当前位置：
首页
>
产品中心 >
Other_reagents >
Adipogen/IAXO-102 (CD14/TLR4 Antagonist) (synthetic)/IAX-600-002-M005/5 mg
Adipogen/IAXO-102 (CD14/TLR4 Antagonist) (synthetic)/IAX-600-002-M005/5 mg
商品编号：
IAX-600-002-M005
品牌：
Adipogen Inc
市场价：
¥8500.00
美元价：
5100.00
产品分类：
其他试剂
公司分类：
Other_reagents
联系Q Q：
3392242852
电话号码：
4000-520-616
电子邮箱：
info@ebiomall.com
商品介绍
| ProductDetails | |
|---|---|
| Synonyms | Methyl6-deoxy-6-amino-2,3-di-O-tetradecyl-α-D-glucopyranoside |
| ProductType | Chemical |
| Properties | |
| Formula | C35H71NO5 |
| MW | 585.94g/mol |
| CAS | 1115270-63-7 |
| Source/HostChemicals | Synthetic. |
| PurityChemicals | ≥98%(TLC) |
| Appearance | Whitesolid. |
| Solubility | SolubleinMethanol,DMSOandEthanol1:1(vol:vol):>10mM. |
| BIOLOGicalActivity | Describedtointerferewithhuman,ratandmouseTLR4/CD14signaling,otherspeciesnottested.Optimalworkingconcentrationdependsuponthetype,purityandconcentrationandofTLR4ligand,carrierproteinsuchasLPS-bindingprotein(LBP),solubleandmembrane-boundCD14,thepresenceofTLR4co-receptors(e.g.CD36)aswellasontypeandtimeofread-out(e.g.cytokinemeasurementincellculturesupernatant)orthebiologicaloutcomeofinvivoexperimentsandthereforeneedstobedeterminedforeachapplication.Recommendedstartingconcentration:invitro:5μM,invivo(rodent):3mg/kg.Controlcompound:IAXO-201(Cat.No.:IAX-600-004). |
| Identity | DeterminedbyNMRandMS. |
| Declaration | ManufacturedbyInnaxon. |
| OtherProductData | Reconstitution:Fora2mMstocksolution,dissolvetotalvialcontentin853μl(1mgsize)or4,266μl(5mgsize)in(1:1)DMSO/Ethanol(vol:vol). |
| InChiKey | InChI=1/C35H71NO5/c1-4-6-8-10-12-14-16-18-20-22-24-26-28-39-33-32(37)31(30-36)41-35(38-3)34(33)40-29-27-25-23-21-19-17-15-13-11-9-7-5-2/h31-35,37H,4-30,36H2,1-3H3 |
| ShippingandHandling | |
| Shipping | AMBIENT |
| ShortTermStorage | +4°C |
| LongTermStorage | +4°C |
| Use/StABIlity | Stableforatleast1yearafterreceiptwhenstoredat+4°C. |
| Documents | |
| MSDS |  DownloadPDF |
| ProductSpecificationSheet | |
| Datasheet | DownloadPDF |
- CD14/TLR4antagoNIST.Inhibitorofsterileinflammation.
- SyntheticTLR4/CD14ligandwithTLR4modulatingactivitiesinvitro,andconferringprotectionagainstTLR4/CD14-mediatedtissuedamageandinflammationinvivo.UsefultoexploreCD14-dependentandTLR4-independentpathwaysandTLR4activationbyendogenousligands(e.g.hyaluronicacidoligosaccharides,oxLDL,HMGB1)insterileinflammation.Showntoinhibitneuropathicpain,secondarynecrosisofacutedrug-inducedliverfailureandvascularinflammation,andaBDominalaorticaneurysmbyblockingnon-hematopoieticTLR4signaling.Usefultool,whereinhibitionofsterile(auto-)inflammationisdesired,withoutcompromisingTLR4’skeyroleinthedefenseofpathogens.
ProductReferences
- Inhibitionoflipidastimulatedactivationofhumandendriticcellsandmacrophagesbyaminoandhydroxylaminomonosaccharides:F.Peri,etal.;Angew.Chem.46,3308(2007)
- TLR4receptorasnewtargettotreatneuropathicpain:efficacyofanewreceptorantagonistinamodelofperipheralnerveinjuryinmice:I.Bettoni,etal.;Glia56,1312(2008)
- Glycolipidsandbenzylammoniumlipidsasnovelantisepsisagents:synthesisandbiologicalcharacterization:M.Piazza,etal.;J.Med.Chem.52,1209(2009)
- EvidenceofaspecificinteractionbetweennewsyntheticantisepsisagentsandCD14:M.Piazza,etal.;Biochemistry48,12337(2009)
- ExploringtheLPS/TLR4signalpathwaywithsmallmolecules:F.Peri,etal.;Biochem.Soc.Trans.38,1390(2010)(Review)
- TherapeutictargetingofinnateimmunitywithToll-likereceptor4(TLR4)antagonists:F.Peri&M.Piazza;Biotechnol.Adv.30,251(2012)(Review)
- SyntheticmoleculesandfunctionalizednanoparticlestargetingtheLPS-TLR4signaling:Anewgenerationofimmunotherapeutics:F.Peri,etal.;PureAppl.Chem.84,97(2012)(Review)
- Tolllikereceptor4antagonistpreventsacetaminopheninducedacuteliverfailureinmice:anoveltherapeuticstrategy:N.Shah,etal.;Gut61,A28(2012)
- Multivalentglycoconjugatesasanti-pathogenicagents.A.Bernardi,etal.;Chem.Soc.Rev.42,4709(2013)(Review)
- Toll-likereceptor4(TLR4)modulationbysyntheticandnaturalcompounds:anupdate:F.Peri&V.Calabrese;Med.Chem.57,3612(2014)(Review)
- AnovelsmallmimeticmoleculeTLR4antagonist(IAXO-102)modulatesTLR4proinflammatorysignallingandinhibitsaorticaneurysmsdevelopment:C.Huggins,etal.;Atherosclerosis241,e53(2015)
品牌介绍
Adipogen公司由三个子公司组成，分别是Adipogen,Inc.(韩国),AdipogenSA(瑞士)和 AdipogenCorporation(美国圣地亚哥)。总部设在美国，运营总部在瑞士利斯塔尔。Adipogen公司专门从事生命科学研究试剂的开发，如癌症、免疫、炎症、代谢疾病（糖尿病、肥胖）、干细胞和神经退行性疾病等领域。其重点关注开发创新优质的ELISA试剂盒。另外，也可提供抗体和蛋白产品，Adipogen拥有自己的化学实验室，致力于开发创新型小分子化合物。
联络我们
